Antonio Piralla
A5018871332- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Cytomegalovirus and herpesvirus research
- SARS-CoV-2 detection and testing
- Parvovirus B19 Infection Studies
- Animal Virus Infections Studies
- Animal Disease Management and Epidemiology
- Herpesvirus Infections and Treatments
- Pneumonia and Respiratory Infections
- Long-Term Effects of COVID-19
- COVID-19 epidemiological studies
- Virology and Viral Diseases
- Virus-based gene therapy research
- Immunodeficiency and Autoimmune Disorders
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Bacillus and Francisella bacterial research
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Bacteriophages and microbial interactions
- COVID-19 and healthcare impacts
Policlinico San Matteo Fondazione
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Bambino Gesù Children's Hospital
2023-2024
University of Pavia
2010-2022
Monitoring the adaptive immune responses during natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection provides useful information for development vaccination strategies against this virus and its emerging variants. We thus profiled serum anti-SARS-CoV-2 antibody (Ab) levels specific memory B T cell in convalescent coronavirus disease 2019 (COVID-19) patients.
The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and urgent need to study more efficient vaccination strategies. Here we observed that an mRNA booster in individuals vaccinated with two doses inactivated significantly increased plasma level specific antibodies bind receptor-binding domain (RBD) or spike (S) ectodomain (S1 + S2) both G614 variants, compared homologous vaccine. RBD- S-specific IgG virus neutralization titers against variants concern...
Neutralizing antibodies that target the receptor-binding domain (RBD) of SARS-CoV-2 spike protein are among most promising approaches against COVID-191,2. A bispecific IgG1-like molecule (CoV-X2) has been developed on basis C121 and C135, two derived from donors who had recovered COVID-193. Here we show CoV-X2 simultaneously binds independent sites RBD and, unlike its parental antibodies, prevents detectable binding to cellular receptor virus, angiotensin-converting enzyme 2 (ACE2)....
Abstract From February to April 2020, Lombardy (Italy) reported the highest numbers of SARS-CoV-2 cases worldwide. By analyzing 346 whole genomes, we demonstrate presence seven viral lineages in Lombardy, frequently sustained by local transmission chains and at least two likely have originated Italy. Six single nucleotide polymorphisms (five them non-synonymous) characterized sequences, none affecting N-glycosylation sites. The lineages, clusters within three them, revealed that community...
The COVID-19 pandemic is caused by the betacoronavirus SARS-CoV-2. In November 2021, Omicron variant was discovered and immediately classified as a of concern (VOC), since it shows substantially more mutations in spike protein than any previous variant, especially receptor-binding domain (RBD). We analyzed binding RBD to human angiotensin-converting enzyme-2 receptor (ACE2) ability sera from patients or vaccinees comparison Wuhan, Beta, Delta variants.
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the efficacy vaccines and antiviral monoclonal antibodies. Continued development immunotherapies vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions virus spike glycoprotein are both functionally relevant averse change, we identified human neutralizing antibodies highly conserved epitopes....
Mosquito-borne West Nile virus (WNV) infection is benign in most individuals but can cause encephalitis <1% of infected individuals. We show that ∼35% patients hospitalized for WNV disease (WNVD) six independent cohorts from the EU and USA carry auto-Abs neutralizing IFN-α and/or -ω. The prevalence these antibodies highest with (∼40%), silent as low general population. odds ratios WNVD relative to those without them population range 19.0 (95% CI 15.0–24.0, P value <10–15) only...
The emergence of Omicron lineages and descendent subvariants continues to present a severe threat the effectiveness vaccines therapeutic antibodies. We have previously suggested that an insufficient mucosal immunoglobulin A (IgA) response induced by mRNA is associated with surge in breakthrough infections. Here, we further show intramuscular and/or inactivated cannot sufficiently boost secretory IgA uninfected individuals, particularly against variant. thus engineered characterized...
In order to investigate the genetic diversity and patterns of co-circulating genotypes respiratory syncytial virus (RSV) their possible relationships with severity RSV infection, we studied all RSV-positive nasopharyngeal samples collected from children during five consecutive winters (2009–2010, 2010–2011, 2011–2012, 2012–2013 2013–2014). The RSVs were detected using panel fast assay single-tube RT-PCR, nucleotides sequenced, they tested for positive selection. Of 165 samples, 131 (79.4%)...
The management of mother-infant dyads during the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic constitutes a major issue for neonatologists. In mothers with SARS-CoV-2 infection, current recommendations suggest either to separate dyad or encourage protected rooming-in under appropriate precautions. No data are available regarding risk mother-to-infant transmission rooming-in.To evaluate postnatal from infected their neonates following and breastfeeding.A...
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. is detected 33 subjects, with a 100-day cumulative incidence 0.93%. protection against acquisition 83% (95%CI: 58-93%) the overall population and 93% 69-99%) SARS-CoV-2-experienced when compared non-vaccinated control group from same Institution, which occurs 20/346 subjects (100-day incidence: 5.78%). The symptomatic 16 (48%) vaccinated vs 17 (85%) controls (p = 0.01). All...
We report a rapid increase in enterovirus D68 (EV-D68) infections, with 139 cases reported from eight European countries between 31 July and 14 October 2021. This upsurge is line the seasonality of EV-D68 was presumably stimulated by widespread reopening after COVID-19 lockdown. Most were identified September, but more are to be expected coming months. Reinforcement clinical awareness, diagnostic capacities surveillance urgently needed Europe.
In August 2023, six locally acquired dengue virus 1 infections were detected in Lodi province, Lombardy Region, northern Italy, where the vector Aedes albopictus is present. Four cases hospitalised, none died. The viruses clustered with Peruvian and Brazilian strains collected between 2021 2023. This preliminary report highlights importance of continued integrated surveillance imported vector-borne potential for tropical disease outbreaks highly populated regions Italy competent vectors are
Echovirus 11 (E11) has recently been associated with a series of nine neonatal cases severe hepatitis in France. Here, we present caused by E11 pair twins. In one the neonates, clinical picture evolved to fulminant hepatitis. The genome showed 99% nucleotide identity strains reported Rapid characterisation using next generation sequencing is essential identify new and more pathogenetic variants.